Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2004

Open Access 01-09-2004 | Research article

Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease

Authors: Vera Sobek, Nico Birkner, Ingrid Falk, Andreas Würch, Carsten J Kirschning, Hermann Wagner, Reinhard Wallich, Marinus C Lamers, Markus M Simon

Published in: Arthritis Research & Therapy | Issue 5/2004

Login to get access

Abstract

The pathogenesis of chronic inflammatory joint diseases such as adult and juvenile rheumatoid arthritis and Lyme arthritis is still poorly understood. Central to the various hypotheses in this respect is the notable involvement of T and B cells. Here we develop the premise that the nominal antigen-independent, polyclonal activation of preactivated T cells via Toll-like receptor (TLR)-2 has a pivotal role in the initiation and perpetuation of pathogen-induced chronic inflammatory joint disease. We support this with the following evidence. Both naive and effector T cells express TLR-2. A prototypic lipoprotein, Lip-OspA, from the etiological agent of Lyme disease, namely Borrelia burgdorferi, but not its delipidated form or lipopolysaccharide, was able to provide direct antigen-nonspecific co-stimulatory signals to both antigen-sensitized naive T cells and cytotoxic T lymphocyte (CTL) lines via TLR-2. Lip-OspA induced the proliferation and interferon (IFN)-γ secretion of purified, anti-CD3-sensitized, naive T cells from C57BL/6 mice but not from TLR-2-deficient mice. Induction of proliferation and IFN-γ secretion of CTL lines by Lip-OspA was independent of T cell receptor (TCR) engagement but was considerably enhanced after suboptimal TCR activation and was inhibitable by monoclonal antibodies against TLR-2.
Appendix
Available only for authorised users
Literature
1.
Steere AC, Gross D, Meyer AL, Huber BT: Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis. J Autoimmun. 2001, 16: 263-268. 10.1006/jaut.2000.0495.CrossRefPubMed
2.
Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423: 356-361. 10.1038/nature01661.CrossRefPubMed
3.
Klinman D: Does activation of the innate immune system contribute to the development of rheumatoid arthritis?. Arthritis Rheum. 2003, 48: 590-593. 10.1002/art.10852.CrossRefPubMed
4.
Silman AJ, Hochberg MC: Rheumatoid Arthritis. In Epidemiology of the Rheumatic Diseases. Edited by: Silman AJ, Hochberg MC. 2001, Oxford: Oxford University Press, 31-71.
5.
Hirschfeld M, Kirschning CJ, Schwandner R, Wesche H, Weis JH, Wooten RM, Weis JJ: Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol. 1999, 163: 2382-2386.PubMed
6.
Medzhitov R, Janeway CA: How does the immune system distinguish self from nonself?. Semin Immunol. 2000, 12: 185-188. 10.1006/smim.2000.0230. discussion 257–344CrossRefPubMed
7.
Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol. 2001, 1: 135-145. 10.1038/35100529.CrossRefPubMed
8.
Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376. 10.1146/annurev.immunol.21.120601.141126.CrossRefPubMed
9.
Matsuguchi T, Takagi K, Musikacharoen T, Yoshikai Y: Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes. Blood. 2000, 95: 1378-1385.PubMed
10.
Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002, 168: 4531-4537.CrossRefPubMed
11.
van der Heijden IM, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM, Hazenberg MP, Breedveld FC, Tak PP: Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum. 2000, 43: 593-598. 10.1002/1529-0131(200003)43:3<593::AID-ANR16>3.0.CO;2-1.CrossRefPubMed
12.
Ronaghy A, Prakken BJ, Takabayashi K, Firestein GS, Boyle D, Zvailfler NJ, Roord ST, Albani S, Carson DA, Raz E: Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J Immunol. 2002, 168: 51-56.CrossRefPubMed
13.
Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA, Seyer JM: Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity. 1995, 22: 137-147.CrossRefPubMed
14.
15.
Yssel H, Shanafelt MC, Soderberg C, Schneider PV, Anzola J, Peltz G: Borrelia burgdorferi activates a T helper type 1-like T cell subset in Lyme arthritis. J Exp Med. 1991, 174: 593-601. 10.1084/jem.174.3.593.CrossRefPubMed
16.
Li NL, Zhang DQ, Zhou KY, Cartman A, Leroux JY, Poole AR, Zhang YP: Isolation and characteristics of autoreactive T cells specific to aggrecan G1 domain from rheumatoid arthritis patients. Cell Res. 2000, 10: 39-49.CrossRefPubMed
17.
Verheijden GF, Rijnders AW, Bos E, Coenen-de Roo CJ, van Staveren CJ, Miltenburg AM, Meijerink JH, Elewaut D, de Keyser F, Veys E, et al: Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum. 1997, 40: 1115-1125.CrossRefPubMed
18.
Benoist C, Mathis D: Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?. Nat Immunol. 2001, 2: 797-801. 10.1038/ni0901-797.CrossRefPubMed
19.
20.
Matsuyama T, Yamada A, Kay J, Yamada KM, Akiyama SK, Schlossman SF, Morimoto C: Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. J Exp Med. 1989, 170: 1133-1148. 10.1084/jem.170.4.1133.CrossRefPubMed
21.
Shimizu Y, van Seventer GA, Horgan KJ, Shaw S: Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol. 1990, 145: 59-67.PubMed
22.
Brett SJ, Mazurov AV, Charles IG, Tite JP: The invasin protein of Yersinia spp. provides co-stimulatory activity to human T cells through interaction with beta 1 integrins. Eur J Immunol. 1993, 23: 1608-1614.CrossRefPubMed
23.
Simon MM, Nerz G, Kramer MD, Hurtenbach U, Schaible UE, Wallich R: The outer surface lipoprotein A of Borrelia burgdorferi provides direct and indirect augmenting/co-stimulatory signals for the activation of CD4+ and CD8+ T cells. Immunol Lett. 1995, 45: 137-142. 10.1016/0165-2478(94)00243-K.CrossRefPubMed
24.
Knigge H, Simon MM, Meuer SC, Kramer MD, Wallich R: The outer surface lipoprotein OspA of Borrelia burgdorferi provides co- stimulatory signals to normal human peripheral CD4+ and CD8+ T lymphocytes. Eur J Immunol. 1996, 26: 2299-2303.CrossRefPubMed
25.
Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul WE: B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol. 1986, 136: 4538-4541.PubMed
26.
Karnowski A, Yu P, Achatz G, Lamers MC: The road to the production of IgE is long and winding. Am J Respir Crit Care Med. 2000, 162: S71-S75.CrossRefPubMed
27.
Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998, 282: 2085-2088. 10.1126/science.282.5396.2085.CrossRefPubMed
28.
Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M: Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med. 1998, 188: 2091-2097. 10.1084/jem.188.11.2091.PubMedCentralCrossRefPubMed
29.
Werts C, Tapping RI, Mathison JC, Chuang TH, Kravchenko V, Saint Girons I, Haake DA, Godowski PJ, Hayashi F, Ozinsky A, et al: Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol. 2001, 2: 346-352. 10.1038/86354.CrossRefPubMed
30.
Poltorak A, Merlin T, Nielsen PJ, Sandra O, Smirnova I, Schupp I, Boehm T, Galanos C, Freudenberg MA: A point mutation in the IL-12R beta 2 gene underlies the IL-12 unresponsiveness of Lps-defective C57BL/10ScCr mice. J Immunol. 2001, 167: 2106-2111.CrossRefPubMed
31.
Schaible UE, Kramer MD, Eichmann K, Modolell M, Museteanu C, Simon MM: Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci USA. 1990, 87: 3768-3772.PubMedCentralCrossRefPubMed
32.
Simon MM, Hausmann M, Tran T, Ebnet K, Tschopp J, Tha Hla R, Mullbacher A: In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A × B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med. 1997, 186: 1781-1786. 10.1084/jem.186.10.1781.PubMedCentralCrossRefPubMed
33.
Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, Luppa PB, Ebel F, Busch DH, Bauer S, et al: Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest. 2004, 113: 1473-1481. 10.1172/JCI200420762.PubMedCentralCrossRefPubMed
34.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162: 156-159. 10.1006/abio.1987.9999.CrossRefPubMed
35.
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P: Molecular Biology of the Cell. 2002, New York: Garland Science, 4
36.
Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA: Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med. 2002, 8: 878-884.PubMed
37.
Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S: Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol. 2002, 169: 10-14.CrossRefPubMed
38.
Akira S: Mammalian Toll-like receptors. Curr Opin Immunol. 2003, 15: 5-11. 10.1016/S0952-7915(02)00013-4.CrossRefPubMed
39.
Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A: The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA. 2000, 97: 13766-13771. 10.1073/pnas.250476497.PubMedCentralCrossRefPubMed
40.
Bulut Y, Faure E, Thomas L, Equils O, Arditi M: Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol. 2001, 167: 987-994.CrossRefPubMed
41.
Morr M, Takeuchi O, Akira S, Simon MM, Muhlradt PF: Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol. 2002, 32: 3337-3347. 10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I.CrossRefPubMed
42.
Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature. 2000, 406: 782-787. 10.1038/35021228.CrossRefPubMed
43.
Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R: Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001, 2: 947-950. 10.1038/ni712.CrossRefPubMed
44.
Applequist SE, Wallin RP, Ljunggren HG: Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol. 2002, 14: 1065-1074. 10.1093/intimm/dxf069.CrossRefPubMed
45.
Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM: Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol. 2001, 166: 249-255.CrossRefPubMed
46.
Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J: Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003, 197: 403-411. 10.1084/jem.20021633.PubMedCentralCrossRefPubMed
47.
Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K: Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002, 3: 667-672.PubMed
48.
Ulevitch RJ, Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995, 13: 437-457. 10.1146/annurev.iy.13.040195.002253.CrossRefPubMed
49.
Imler JL, Hoffmann JA: Toll signaling: the TIReless quest for specificity. Nat Immunol. 2003, 4: 105-106. 10.1038/ni0203-105.CrossRefPubMed
50.
O'Neill LA: Wanted: a molecular basis for specificity in toll-like receptor signal transduction. Mol Cell. 2002, 10: 969-971. 10.1016/S1097-2765(02)00754-2.CrossRefPubMed
51.
Barton GM, Medzhitov R: Toll-like receptor signaling pathways. Science. 2003, 300: 1524-1525. 10.1126/science.1085536.CrossRefPubMed
52.
Kane LP, Lin J, Weiss A: It's all Rel-ative: NF-κB and CD28 costimulation of T-cell activation. Trends Immunol. 2002, 23: 413-420. 10.1016/S1471-4906(02)02264-0.CrossRefPubMed
53.
Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 1999, 285: 736-739. 10.1126/science.285.5428.736.CrossRefPubMed
54.
Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, Maitland M, Norgard MV, Plevy SE, Smale ST, et al: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 1999, 285: 732-736. 10.1126/science.285.5428.732.CrossRefPubMed
55.
Mackey MF, Barth RJ, Noelle RJ: The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol. 1998, 63: 418-428.PubMed
56.
Itoh Y, Germain RN: Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4+ T cells. J Exp Med. 1997, 186: 757-766. 10.1084/jem.186.5.757.PubMedCentralCrossRefPubMed
57.
Preckel T, Breloer M, Kohler H, von Bonin A, Weltzien HU: Partial agonism and independent modulation of T cell receptor and CD8 in hapten-specific cytotoxic T cells. Eur J Immunol. 1998, 28: 3706-3718. 10.1002/(SICI)1521-4141(199811)28:11<3706::AID-IMMU3706>3.0.CO;2-7.CrossRefPubMed
58.
Krieg AM, Steinberg AD: Retroviruses and autoimmunity. J Autoimmun. 1990, 3: 137-166. 10.1016/0896-8411(90)90137-H.CrossRefPubMed
59.
Rook GA, Stanford JL: Slow bacterial infections or autoimmunity?. Immunol Today. 1992, 13: 160-164. 10.1016/0167-5699(92)90119-R.CrossRefPubMed
60.
Ogata H, Su I, Miyake K, Nagai Y, Akashi S, Mecklenbrauker I, Rajewsky K, Kimoto M, Tarakhovsky A: The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med. 2000, 192: 23-29. 10.1084/jem.192.1.23.PubMedCentralCrossRefPubMed
61.
Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ: B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev. 2000, 176: 154-170. 10.1034/j.1600-065X.2000.00607.x.CrossRefPubMed
62.
Zanin-Zhorov A, Nussbaum G, Franitza S, Cohen IR, Lider O: T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. FASEB J. 2003, 17: 1567-1569.PubMed
63.
Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL: Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979, 301: 5-8.CrossRefPubMed
64.
Kaplan C, Valdez JC, Chandrasekaran R, Eibel H, Mikecz K, Glant TT, Finnegan A: Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis. Arthritis Res. 2002, 4: 54-58. 10.1186/ar383.PubMedCentralCrossRefPubMed
65.
Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR: The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 2001, 3: 136-141. 10.1186/ar290.PubMedCentralCrossRefPubMed
66.
Yin Z, Siegert S, Neure L, Grolms M, Liu L, Eggens U, Radbruch A, Braun J, Sieper J: The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology (Oxford). 1999, 38: 1058-1067. 10.1093/rheumatology/38.11.1058.CrossRef
67.
Johnston YE, Duray PH, Steere AC, Kashgarian M, Buza J, Malawista SE, Askenase PW: Lyme arthritis. Spirochetes found in synovial microangiopathic lesions. Am J Pathol. 1985, 118: 26-34.PubMedCentralPubMed
68.
Schaible UE, Gay S, Museteanu C, Kramer MD, Zimmer G, Eichmann K, Museteanu U, Simon MM: Lyme borreliosis in the severe combined immunodeficiency (scid) mouse manifests predominantly in the joints, heart, and liver. Am J Pathol. 1990, 137: 811-820.PubMedCentralPubMed
69.
Schaible UE, Kramer MD, Wallich R, Tran T, Simon MM: Experimental Borrelia burgdorferi infection in inbred mouse strains: antibody response and association of H-2 genes with resistance and susceptibility to development of arthritis. Eur J Immunol. 1991, 21: 2397-2405.CrossRefPubMed
70.
Barthold SW, de Souza MS, Janotka JL, Smith AL, Persing DH: Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol. 1993, 143: 959-971.PubMedCentralPubMed
71.
Whitmire WM, Garon CF: Specific and nonspecific responses of murine B cells to membrane blebs of Borrelia burgdorferi. Infect Immun. 1993, 61: 1460-1467.PubMedCentralPubMed
72.
Steere AC, Dwyer E, Winchester R: Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med. 1990, 323: 219-223.CrossRefPubMed
73.
Steere AC: Clinical definitions and differential diagnosis of Lyme arthritis. Scand J Infect Dis Suppl. 1991, 77: 51-54.PubMed
74.
Barthold SW, Beck DS, Hansen GM, Terwilliger GA, Moody KD: Lyme borreliosis in selected strains and ages of laboratory mice. J Infect Dis. 1990, 162: 133-138.CrossRefPubMed
75.
Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, Field JA, Steere AC, Huber BT: Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 1998, 281: 703-706. 10.1126/science.281.5377.703.CrossRefPubMed
76.
Trollmo C, Meyer AL, Steere AC, Hafler DA, Huber BT: Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1 alpha L is a partial agonist for outer surface protein A-reactive T cells. J Immunol. 2001, 166: 5286-5291.CrossRefPubMed
77.
Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT: Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 2003, 48: 534-540. 10.1002/art.10772.CrossRefPubMed
78.
Steere AC, Glickstein L: Elucidation of Lyme arthritis. Nat Rev Immunol. 2004, 4: 143-152. 10.1038/nri1267.CrossRefPubMed
79.
Kalish RS, Wood JA, Golde W, Bernard R, Davis LE, Grimson RC, Coyle PK, Luft BJ: Human T lymphocyte response to Borrelia burgdorferi infection: no correlation between human leukocyte function antigen type 1 peptide response and clinical status. J Infect Dis. 2003, 187: 102-108. 10.1086/346059.CrossRefPubMed
80.
Mackay CR, Marston W, Dudler L: Altered patterns of T cell migration through lymph nodes and skin following antigen challenge. Eur J Immunol. 1992, 22: 2205-2210.CrossRefPubMed
81.
Mackay CR: Migration pathways and immunologic memory among T lymphocytes. Semin Immunol. 1992, 4: 51-58.PubMed
Metadata
Title
Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease
Authors
Vera Sobek
Nico Birkner
Ingrid Falk
Andreas Würch
Carsten J Kirschning
Hermann Wagner
Reinhard Wallich
Marinus C Lamers
Markus M Simon
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1212

Other articles of this Issue 5/2004

Arthritis Research & Therapy 5/2004 Go to the issue

Research article

Improved cartilage integration and interfacial strength after enzymatic treatment in a cartilage transplantation model

Research article

Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate

Research article

A proinflammatory role for Fas in joints of mice with collagen-induced arthritis

Research article

Critical role of the major histocompatibility complex and IL-10 in matrilin-1-induced relapsing polychondritis in mice

Research article

Estrogen receptor-α gene haplotype is associated with primary knee osteoarthritis in Korean population

Research article

Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits